Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page
- Check7 days agoChange DetectedVersion bumped from 3.5.0 to 3.5.2.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedNaples, Italy, 80131 has been added as a study location and Napoli, Italy, 80131 removed; the study revision version updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. This is a metadata version change and does not alter the study details displayed.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.0%

- Check103 days agoChange Detected- Revision: v3.3.4 updated (replacing v3.3.3). The overall study information on the page remains unchanged.SummaryDifference0.0%

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.